- Home
- GBAB vs CELC Comparison
GBAB vs CELC Comparison
Compare GBAB & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBAB
- CELC
- Stock Information
- Founded
- GBAB 2010
- CELC 2011
- Country
- GBAB United States
- CELC United States
- Employees
- GBAB N/A
- CELC N/A
- Industry
- GBAB Investment Managers
- CELC Medical Specialities
- Sector
- GBAB Finance
- CELC Health Care
- Exchange
- GBAB Nasdaq
- CELC Nasdaq
- Market Cap
- GBAB 387.9M
- CELC 440.7M
- IPO Year
- GBAB N/A
- CELC 2017
- Fundamental
- Price
- GBAB $15.59
- CELC $13.15
- Analyst Decision
- GBAB
- CELC Strong Buy
- Analyst Count
- GBAB 0
- CELC 6
- Target Price
- GBAB N/A
- CELC $30.17
- AVG Volume (30 Days)
- GBAB 69.4K
- CELC 184.2K
- Earning Date
- GBAB 01-01-0001
- CELC 03-26-2025
- Dividend Yield
- GBAB 9.18%
- CELC N/A
- EPS Growth
- GBAB N/A
- CELC N/A
- EPS
- GBAB N/A
- CELC N/A
- Revenue
- GBAB N/A
- CELC N/A
- Revenue This Year
- GBAB N/A
- CELC N/A
- Revenue Next Year
- GBAB N/A
- CELC N/A
- P/E Ratio
- GBAB N/A
- CELC N/A
- Revenue Growth
- GBAB N/A
- CELC N/A
- 52 Week Low
- GBAB $14.22
- CELC $10.35
- 52 Week High
- GBAB $17.44
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- GBAB 50.42
- CELC 60.85
- Support Level
- GBAB $15.36
- CELC $12.55
- Resistance Level
- GBAB $15.63
- CELC $13.25
- Average True Range (ATR)
- GBAB 0.18
- CELC 0.68
- MACD
- GBAB -0.02
- CELC 0.14
- Stochastic Oscillator
- GBAB 41.27
- CELC 85.79
About GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest
Guggenheim Taxable Municipal Managed Duration Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.